Effect of N-terminal pro B-type natriuretic peptide levels on the efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of Japanese patients with uncontrolled essential hypertension: a subanalysis of the EXCITE-HT study

Figures

• 

  Fig. 1. Changes from baseline to EOT in A–D morning home, E, F bedtime home, and G, H office BP (full analysis set). A, C, E, G Low NT-proBNP subgroup (<125 pg/mL); B, D, F, H high NT-proBNP subgroup (≥ 125 pg/mL). For panels C and D, the red dotted line (3.9 mmHg) and blue dotted line (2.1 mmHg) indicate the non-inferiority criteria. Data are LS mean (95% CI) for panels (A–D). Data are arithmetic mean (95% CI) for panels (E–H). ***P < 0.001 versus baseline, paired t-test. BP blood pressure, CI confidence interval, DBP diastolic blood pressure, EOT end of treatment, LS least squares, NT-proBNP N-terminal pro B-type natriuretic peptide, SBP systolic blood pressure

• 

  Fig. 2. Percentage change in geometric mean UACR (A, B) and change from baseline in NT-proBNP (C, D) at Week 12 (full analysis set). A, C Low NT-proBNP subgroup (<125 pg/mL); B, D high NT-proBNP subgroup (≥125 pg/mL). Data are mean (95% CI). *P < 0.05 versus baseline, paired t-test. ***P < 0.001 versus baseline, paired t-test. CI confidence interval, NT-proBNP N-terminal pro B-type natriuretic peptide, SD standard deviation, UACR urinary albumin-to-creatinine ratio

• 

  Fig. 3. Time course changes in eGFRcreat (A, B) and serum potassium levels (C, D) during the study period (safety analysis set). A, C Low NT-proBNP subgroup (<125 pg/mL); B, D high NT-proBNP subgroup (≥125 pg/mL). Data are mean ± SD. In the figure key, n = number of patients at baseline. The number of patients differed at each measurement timepoint. eGFRcreat creatinine-based estimated glomerular filtration rate, NT-proBNP N-terminal pro B-type natriuretic peptide, SD standard deviation